| A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (NCT05383352) | Ipsen | 2022-05-30 |
| Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer (NCT05078775) | Faeth Therapeutics | 2021-12-21 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (NCT04514497) | National Cancer Institute (NCI) | 2021-10-20 |
| Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (NCT04787991) | Cancer Insight, LLC | 2021-08-09 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors (NCT04616534) | National Cancer Institute (NCI) | 2021-06-01 |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (NCT04387071) | University of Southern California | 2021-04-29 |
| Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (NCT04548752) | National Cancer Institute (NCI) | 2021-02-22 |
| iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation (NCT03608631) | M.D. Anderson Cancer Center | 2021-01-27 |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. (NCT04348045) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2020-12-07 |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. (NCT04652206) | Scandion Oncology A/S | 2020-10-27 |
| Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer (NCT04524702) | Emory University | 2020-09-14 |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (NCT04233866) | ECOG-ACRIN Cancer Research Group | 2020-08-26 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer (NCT04058964) | M.D. Anderson Cancer Center | 2020-02-01 |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer (NCT04191421) | Emory University | 2020-01-17 |
| Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer (NCT04132505) | M.D. Anderson Cancer Center | 2019-10-22 |
| SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer (NCT04050085) | University of California, Davis | 2019-08-15 |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors (NCT02757391) | M.D. Anderson Cancer Center | 2019-08-09 |
| Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (NCT03974854) | Centre Hospitalier Universitaire de Besancon | 2019-07-08 |
| Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma (NCT03943667) | UNICANCER | 2019-05-23 |
| Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer (NCT03910387) | Emory University | 2019-04-17 |
| A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer (NCT03816163) | Astellas Pharma Global Development, Inc. | 2019-03-15 |
| Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (NCT03337087) | Academic and Community Cancer Research United | 2018-11-02 |
| MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (NCT03611556) | MedImmune LLC | 2018-06-21 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (NCT03257761) | University of Southern California | 2018-02-07 |
| Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer (NCT03006302) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-01-31 |
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers (NCT03368963) | Emory University | 2018-01-30 |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer (NCT03331562) | Translational Genomics Research Institute | 2017-12-27 |
| BATs Treatment for Pancreatic Cancer, Phase Ib/II (NCT03269526) | University of Virginia | 2017-07-28 |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer (NCT03095781) | Emory University | 2017-07-07 |
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer (NCT02847000) | Yogen Saunthararajah | 2016-12-20 |
| Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer (NCT02907099) | M.D. Anderson Cancer Center | 2016-12-01 |
| Olaparib in Treating Patients With Stage IV Pancreatic Cancer (NCT02677038) | M.D. Anderson Cancer Center | 2016-11-11 |
| FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (NCT02890355) | National Cancer Institute (NCI) | 2016-10-27 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer (NCT02383433) | Case Comprehensive Cancer Center | 2016-06-14 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT02567396) | National Cancer Institute (NCI) | 2016-06-01 |
| Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer (NCT02671890) | Mayo Clinic | 2016-02-25 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (NCT02620865) | Barbara Ann Karmanos Cancer Institute | 2015-12-01 |
| Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer (NCT02562898) | Margaret Tempero | 2015-10-12 |
| Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02495896) | University of Southern California | 2015-09-03 |
| Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) (NCT02436668) | Pharmacyclics LLC. | 2015-05-01 |
| Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer (NCT02324543) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-02-01 |
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer (NCT02227940) | Roswell Park Cancer Institute | 2015-01-08 |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer (NCT02333188) | University of Chicago | 2014-12-01 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT02194829) | National Cancer Institute (NCI) | 2014-08-19 |
| A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (NCT02231723) | Sumitomo Pharma America, Inc. | 2014-08-01 |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer (NCT02077881) | NewLink Genetics Corporation | 2014-08-01 |
| A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer (NCT02048384) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-06-10 |
| Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer (NCT01954992) | Eleison Pharmaceuticals LLC. | 2014-04-01 |
| Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma (NCT02117258) | Zeria Pharmaceutical | 2014-04-01 |
| S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (NCT01959139) | SWOG Cancer Research Network | 2014-01-23 |
| Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer (NCT01830322) | Cornerstone Pharmaceuticals | 2014-01-01 |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer (NCT02045589) | Theriva Biologics SL | 2014-01-01 |
| FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (NCT01896869) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-11-01 |
| First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. (NCT01964287) | Institut du Cancer de Montpellier - Val d'Aurelle | 2013-09-24 |
| ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer (NCT01825603) | University of Nebraska | 2013-04-09 |
| A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors (NCT01562899) | Pfizer | 2012-08-27 |
| Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT01660971) | National Cancer Institute (NCI) | 2012-07-30 |
| Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer (NCT01729481) | Ludwig-Maximilians - University of Munich | 2012-07-01 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01585805) | National Cancer Institute (NCI) | 2012-05-15 |
| The Study of Metastatic Pancreatic Adenocarcinoma (NCT01415713) | National Health Research Institutes, Taiwan | 2012-03-01 |
| Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol (NCT01760252) | Beth Israel Medical Center | 2011-12-01 |
| Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (NCT01360853) | Traws Pharma, Inc. | 2011-05-01 |
| Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma (NCT01233375) | Clovis Oncology, Inc. | 2011-04-01 |
| Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma (NCT01204372) | Institut du Cancer de Montpellier - Val d'Aurelle | 2010-06-01 |
| A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) (NCT01124786) | Clovis Oncology, Inc. | 2010-05-01 |
| Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer (NCT02575508) | Roswell Park Cancer Institute | |